New antimycobacterial agents and combined treatment regimens are being
introduced for the treatment of leprosy. Ofloxacin is one such broad
spectrum antimicrobial agent. In this study rifampicin plus ofloxacin
were administered daily for 4 weeks (daily supervised dose). Two patie
nts (and possibly a third patient who refused all investigations) out
of 125 patients developed leucocytopenia during the third week of ther
apy. It was associated with fever, malaise, nausea and loss of appetit
e. They recovered after cessation of drug treatment. Patients receivin
g ofloxacin should be monitored for constitutional symptoms suggestive
of this complication even though the risk of such complication may be
minimal.